Apollo Hospitals Enterprise Ltd

Q1 FY26Healthcare Services

Apollo Hospitals Enterprise Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹8,693

Market cap₹1.3L Cr

P/E61.0

Updated23 Aug 2026

Read5 min read

The short version

Digital business: Expected steady growth of 20%-25% year-on-year once breakeven is achieved, with revenue growth more muted initially due to ongoing investments (Page 14). - Offline pharmacy: Plans to add about 600 stores this year with quarterly additions of ~120 stores; revenue growth targeted at 17%-18% with focus on Central and South regions (Page 14). - Hospital business: Organic growth expected to rise from 11% to mid-teens (~13%-14%), driven by bed expansions and improved occupancy; new hospitals to add around 10% growth over 2-3 years (Pages 7,9,14). - Digital GMV forecast: Rs. Hospital business expects organic growth of 13%-14% on existing assets, with an additional 10% growth from new beds over 2-3 years. - EBITDA margins targeted to expand to around 25% in hospitals; new hospital losses capped around Rs.

From Apollo Hospitals Enterprise Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Digital business: Expected steady growth of 20%-25% year-on-year once breakeven is achieved, with revenue growth more muted initially due to ongoing investments (Page 14).
Offline pharmacy: Plans to add about 600 stores this year with quarterly additions of ~120 stores; revenue growth targeted at 17%-18% with focus on Central and South regions (Page 14).
Hospital business: Organic growth expected to rise from 11% to mid-teens (~13%-14%), driven by bed expansions and improved occupancy; new hospitals to add around 10% growth over 2-3 years (Pages 7,9,14).
Digital GMV forecast: Rs. 3,000-3,200 crore for full FY26 with 25%-30% growth over previous year (Page 6).
The business focuses on sustainable growth over astronomical spikes; unit economics and cost rationalization are key areas for margin and growth improvements (Page 14).

Profitability & Margins

Hospital business expects organic growth of 13%-14% on existing assets, with an additional 10% growth from new beds over 2-3 years.
EBITDA margins targeted to expand to around 25% in hospitals; new hospital losses capped around Rs. 150 crore over two years, with minimal overall impact due to strong cash flows.
Digital business aims for break-even by end of FY26, expecting steady profitability thereafter with 20%-25% year-on-year growth; revenue growth muted short-term due to ongoing digital investments.
Apollo HealthCo’s Q1 revenue grew 19% YoY with a 26% YoY increase in consolidated EBITDA; digital business EBITDA improved significantly.
Pharmacy business targets 17%-18% revenue growth with continued store additions, especially in Central and Southern regions.
Overall EBITDA margins expected to remain stable with minor (100 bps) near-term dips during expansion phases, but growth momentum sustained.
International patient volumes expected to improve, contributing positively to revenue growth and margins.

See what Apollo Hospitals Enterprise Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Apollo Hospitals Limited plans to operationalize around 1,577 new beds in FY26, with approximately 700 beds to be operationalized in the current year and the remaining 800+ beds in FY27.
There is ongoing investment in the digital business, including continual investments in digital assets such as patient health records and AI-based services like Ask Apollo.
The Central Reference Laboratory in Chennai was recently opened on 30th April, a state-of-the-art fully automated facility spanning 45,000 square feet, indicating capital expenditure in diagnostics.
The merger with Keimed will unlock synergies in technology, people, costs, and product categories, enabling expansion of pharmacy outlets through economic "dark stores" across India.
The company is actively engaged in building new hospital projects internationally, such as a hospital in Malaysia, reflecting strategic investments in new markets.

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹981 Cr

Rev 1Mar 1

2CHANDAN₹518 Cr

Rev 1Mar 3

3₹66.5K Cr

Rev 2Mar 1

4₹654 Cr

Rev 2Mar 2

5₹38.9K Cr

Rev 2Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The transcript provided from the AHEL Q1 FY26 Earnings Call does not mention any current or future plans for fundraising through debt or equity. Key points related to financials and investments include: - The company is focused on operational efficiency and sustainable growth. - There are ongoing investments in digital assets, such as patient health records and AI (Ask Apollo). - They expect losses of around Rs. 150 crore over two years from new hospitals, which they can absorb due to strong cash flows. - There is no explicit mention of raising funds via debt or equity in the transcript. - The emphasis is on internal cash generation and rationalizing costs, especially with upcoming mergers. Hence, based on the transcript, there is no stated plan for new fundraising through debt or equity at this time.

See what Apollo Hospitals Enterprise Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided does not explicitly mention current or expected order book or pending orders for Apollo Hospitals Limited. The discussion in the transcript mainly covers operational performance, growth strategies, financial metrics, and segment-wise business outlooks such as hospitals, diagnostics, pharmacies, digital business, and international patient flows. Therefore, there is no information available related to order book or pending orders in the content provided.

Apollo Hospitals Enterprise Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹6.6K Cr, net profit ₹551 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Apollo Hospitals's management said in earlier quarters

Others in Healthcare Services this season

Aster DM Quality Care Ltd (Q1 FY26)
Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…
Dr Agarwal's Hea (Q1 FY26)
70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…
Syngene International Ltd (Q1 FY26)
Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…
Yatharth Hospital & Trauma Care Services Ltd (Q1 FY26)
International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…

Compare:vs Max Healthcare Institute Ltd vs Fortis Health.vs Aster DM Quality Care Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Apollo Hospitals Enterprise Ltd Q1 FY26 results?

What is Apollo Hospitals Enterprise Ltd share price analysis?

Apollo Hospitals Enterprise Ltd currently shows a neutral. The stock trades at a P/E of 61.0 with a market cap of ₹128,263 Cr. Investors should review the full earnings analysis for detailed insights.

Is Apollo Hospitals Enterprise Ltd planning capital expenditure?

Apollo Hospitals Limited plans to operationalize around 1,577 new beds in FY26, with approximately 700 beds to be operationalized in the current year and the remaining 800+ beds in FY27.

Keep Apollo Hospitals Enterprise Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.